0
0
Researchers at Stanford Medicine have made a significant discovery that could shift the framework of how autism spectrum disorders (ASD) are treated. In a new study published August 20, 2025, in Science Advances, scientists found that drugs currently explored for epilepsy can reverse autism-like symptoms in a mouse model of the disorder by targeting hyperactivity in a specific brain region known as the reticular thalamic nucleus (RTN). This finding not only deepens understanding of the neurological overlap between autism and epilepsy but also points to novel treatment possibilities for ASD.
Key Findings and Study Overview
The research team, led by senior author Dr. John Huguenard, a professor of neurology and neurological sciences, and first author Dr. Sung-Soo Jang, used genetically modified mice (Cntnap2 knockout mice) that exhibit behaviors analogous to human autism, such as increased sensitivity to sensory stimuli, repetitive actions, social interaction deficits, heightened motor activity, and seizures. By recording neural activity in the RTN—a brain area acting as a gatekeeper regulating sensory information flow to the cerebral cortex—they found this region exhibited abnormal hyperactivity during exposure to stimuli like light or air puffs and during social encounters.
Intriguingly, this hyperactivity also caused bursts of spontaneous activity correlating with seizure events. Epilepsy is known to co-occur disproportionately in people with autism, with prevalence rates of about 30% compared to 1% in the general population. Understanding this connection, the researchers tested an experimental seizure drug, Z944, which notably reversed the autism-like behavioral deficits in these mice.
Additionally, using an advanced technique called Designer Receptors Exclusively Activated by Designer Drugs (DREADD)-based neuromodulation, the team was able to genetically modify neurons in the RTN to control activity levels precisely. Suppressing RTN hyperactivity reversed autism behaviors in the mice, while artificially increasing RTN activity in normal mice induced similar autism-like deficits. This causally links RTN overactivity to autism behaviors in this model.
Expert Commentary and Context
Dr. Elaine Thompson, a neurologist specializing in neurodevelopmental disorders at a leading university hospital, who was not involved in the study, commented on the importance of these findings:
“This research provides compelling evidence for the RTN as a key neural circuit implicated in both epilepsy and autism. It offers exciting new avenues for therapeutic interventions, particularly using drugs that modulate neural excitability—a promising direction for patients with co-occurring epilepsy and autism.”
The thalamocortical circuitry, which includes the RTN, has long been suspected of involvement in autism due to its fundamental role in sensory processing and regulation of cortical activity. Sensory sensitivity and repetitive behaviors—the hallmarks of autism—could stem from disruptions in this network. However, this study is among the first to pinpoint the RTN’s direct role in driving these behaviors.
Implications for Public Health and Autism Treatment
Current treatments for autism spectrum disorder focus largely on behavioral therapies, with very limited pharmacological options available to target core symptoms. The discovery that suppressing RTN hyperactivity can reverse autistic-like behaviors in mice raises hope that manipulated modulation of this brain region could become a therapeutic target for humans. The overlap with epilepsy treatment is especially relevant given the significant comorbidity, suggesting that some epilepsy drugs might be repurposed or optimized to also benefit autistic patients.
This could represent a shift from symptom management alone toward addressing underlying neural mechanisms. However, translating these preliminary findings from mouse models to humans involves complex challenges, including verifying whether the RTN functions similarly and ensuring safety and efficacy in people.
Limitations and Cautions
While the findings are promising, the study is limited to a specific genetic mouse model of autism (Cntnap2 knockout), which may not capture the full spectrum or complexity of human ASD. Autism is a highly heterogeneous disorder with various genetic and environmental causes.
Moreover, Z944 and DREADD-based neuromodulation have yet to be tested in human trials for autism, and long-term effects and potential side effects are not fully known. There is also the challenge of developing tools to target the RTN safely and specifically in people.
Dr. Raj Patel, a clinical neuroscientist focused on autism, notes:
“Animal models provide important insight, but the human brain is far more complex. Careful clinical studies are needed before any epilepsy drug can be recommended for autism treatment.”
Practical Takeaways for Readers
For now, this study highlights the biological connections between epilepsy and autism and underscores the importance of ongoing research into neural circuits to develop better and more targeted therapies. It also emphasizes the value of multidisciplinary approaches combining genetics, neurobiology, and pharmacology to understand and potentially treat neurodevelopmental disorders.
Patients or caregivers should not self-medicate or attempt off-label usage of epilepsy drugs for autism symptoms. Medical advice from qualified professionals remains critical, and any treatment should be pursued under clinical guidance and in the context of approved therapies and trials.
Medical Disclaimer
This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References
- https://medicalxpress.com/news/2025-08-reverse-autism-symptoms-mice-epilepsy.html
